Ascletis Pharma of Hangzhou reported positive Phase IIa trial results from its in-licensed PD-L1 in patients with chronic hepatitis B. ASC22 (envafolimab) is a first-in-class, subcutaneously administered PD-L1 antibody. The Phase IIa trial administered a single dose at three levels to three patients at each level. Eight of the nine patients responded, and one patient in the high-dose cohort had a maximum reduction in HBsAg, the efficacy endpoint. In 2019, Ascletis in-licensed China rights to ASC22 from Suzhou Alphamab for viral indications. More details.... Stock Symbol: (HK: 1672) Share this with colleagues: // //